| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2012-10-18 | Albany Molecular Research (USA) Shire (UK-USA) | undisclosed product | undisclosed | manufacturing |
undisclosed | Production agreement |
| 2012-10-18 | BiondVax Pharmaceuticals (Israel) MonoSol Rx (USA) | M-001 universal influenza vaccine | influenza | R&D |
Infectious diseases | R&D agreement |
| 2012-10-16 | DBV Technologies (France) Centre d'Immunologie de Marseille-Luminy - CIML (France) | mechanisms of actions involved in the epicutaneous treatment of allergies by the EPIT® (Epicutaneous Immunotherapy) method | collaboration |
Allergic diseases - Immune diseases | R&D agreement | |
| 2012-10-16 | Cellectis (France) NIH (USA) | services including generation of induced pluripotent stem (iPS) cell lines of clinical grade and differentiation of iPS cells toward specific tissue cell type of clinical grade. | services |
Services contract | ||
| 2012-10-15 | Meda (Sweden) Jazz Pharmaceuticals (USA) | health products portfolio including Elestrin® | Elestrin® (estradiol gel), Gastrocrom® (cromolyn sodium, USP), Natelle® One (prenatal vitamin), AVCTM Cream (sulfanilamide), Gesticare® DHA (prenatal multi-vitamin), Urelle® (urinary antiseptic) | portfolio acquisition |
Gynecological diseases - Women's health | Product acquisition |
| 2012-10-15 | Pharmaron (China) AstraZeneca (UK) | discovery services in the areas of chemistry, drug metabolism and pharmacokinetics (DMPK), and efficacy screening | services |
Services contract | ||
| 2012-10-15 | Ark Therapeutics (UK) Laurantis Pharma (Finland) | Lymfactin® | breast cancer-associated lymphedema | manufacturing |
Cancer - Oncology | Production agreement |
| 2012-10-15 | ExpreS2ion Biotechnologies (Denmark) - the Jenner Institute (UK) University of Oxford (UK) | ExpreS2ion\'s Drosophila Schneider-2 cell-based technology platform - ExpreS2 - for protein production | licensing |
Licensing agreement | ||
| 2012-10-15 | PolyTherics (UK) undisclosed top five pharmaceutical company | PolyPEG® | services |
Services contract | ||
| 2012-10-15 | Helsinn (Switzerland) Specialised Therapeutics Australia (Australia) | anamorelin | cachexia-anorexia related to non-small cell lung cancer | licensing |
Cancer - Oncology | Licensing agreement |
| 2012-10-12 | Genetic Immunity (USA - Hungary) The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) (Germany) | DNA-based therapeutic vaccine | Human Papilloma Virus (HPV) infection | R&D |
Infectious diseases - Cancer - Oncology | R&D agreement |
| 2012-10-10 | UCB (Belgium), Harvard University (USA) | new immunomodulatory molecules based on the results of intestine studies of the human microbiome (the microbiome is the totality of microbes, their genetic elements and environmental interactions in a particular environment. Adult humans contain, on average, some 100 trillion bacteria in their intestines alone. These bacteria are believed to be central to their host’s well-being while heavily influencing the immune system.) | immunological diseases | R&D |
Immunological diseases | R&D agreement |
| 2012-10-10 | Lonza (Switzerland), NIH Center for Regenerative Medicine (NIH CRM) (USA) | induced pluripotent stem cells (iPSCs) | manufacturing |
Production agreement | ||
| 2012-10-10 | Aeras (USA), GSK (UK) | investigational tuberculosis vaccine | tuberculosis | R&D |
Infectious diseases | R&D agreement |
| 2012-10-10 | Roche (Switzerland) Versant Ventures (USA) Inception Sciences (USA) | drug discovery incubator Inception 3 | sensorineural hearing loss | collaboration |
Otorhinolaryngology | Collaboration agreement |
| 2012-10-10 | Leukocare (Germany) Trillium Diagnostics (USA) | IVD assay kit using the novel biomarker circulating cell-free DNA (cf-DNA) | sepsis | development |
Infectious diseases | Development agreement |
| 2012-10-09 | NovAliX (France) Servier (France) | specific small molecule lead candidates for a novel exploratory target chosen by Servier | undisclosed | R&D |
undisclosed | R&D agreement |
| 2012-10-09 | The Cancer Research Institute (CRI - USA), the Ludwig Institute for Cancer Research, MedImmune (USA - global biologics arm of AstraZeneca (UK) | novel combinations of immunotherapies, including three investigational monoclonal antibodies from MedImmune’s pipeline (Tremelimumab (CTLA-4 blocking antibody), Anti-OX40 Mab, PD-L1 monoclonal Antibody (Anti-B7-H1) or MEDI4736) | solid tumors, cancer | R&D |
Cancer - Oncology | R&D agreement |
| 2012-10-08 | Mucosis (The Netherlands) Crucell, a J&J company (The Netherlands - USA) | Mimopath® platform | R&D |
Infectious diseases | R&D agreement | |
| 2012-10-08 | Lundbeck (Denmark) ImaginAb (USA - CA) | biologics with improved blood-brain barrier transport and imaging agents | collaboration |
CNS diseases | Collaboration agreement |
